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The emergence of a novel inﬂuenza A virus strain into humans poses a continuous pub-
lic health threat. Vaccination is the most effective means of protection against inﬂuenza.
The generation of memory B cells and long-lived plasma cells that can maintain protective
levels of inﬂuenza-speciﬁc antibodies for protracted periods of time is the foundation for
the success of such vaccines. Inﬂuenza vaccines elicit an antibody response that is primar-
ily targeting viral surface glycoproteins. However, frequent amino acid mutations within
the immunodominant epitopes allow the virus to efﬁciently escape neutralization by pre-
existing antibodies and consequently cause annual epidemics and occasional pandemics.
Recently, monoclonal antibodies (mAbs) that target subdominant inﬂuenza epitopes have
been extensively characterized. These epitopes are immunogenic, can mediate virus neu-
tralization, andmost importantly are conserved among different inﬂuenza strains. It remains
puzzling, however, that despite being repeatedly exposed to such conserved domains of
inﬂuenza hemagglutinin (HA) either in the form of vaccination or natural infection, most
humans do not develop immunological memory that can provide broad protection against
emerging virus strains. Here wewill discuss the conditions that may be required for engag-
ing such cross-reactive memory B cells in the immune response to inﬂuenza infection and
vaccination in humans.
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INTRODUCTION
Since the isolation of the ﬁrst human inﬂuenza virus in 1933,
controlling infections mediated by this respiratory pathogen
has represented a formidable challenge (Webby and Webster,
2003). The impediment stems from the ever-evolving nature
of inﬂuenza viruses, which enables the viruses to escape pre-
existing immune surveillance (Kilbourne, 1978). Moreover, effec-
tive vaccines against inﬂuenza viruses work by eliciting anti-
body responses that primarily target the hemagglutinin (HA)
molecule, which is the most variable among virus proteins (Kil-
bourne, 1978). Vaccination remains, however, the most successful
intervention to prevent inﬂuenza virus infection and transmis-
sion (Ellebedy and Webby, 2009). The need for a broadly pro-
tective inﬂuenza vaccine is clearly demonstrated by the failure
of seasonal inﬂuenza vaccines to control the annual epidemics
of inﬂuenza viruses, which result in about three to ﬁve mil-
lion cases of severe illness, and up to 500,000 deaths worldwide
(http://www.who.int/mediacentre/factsheets/fs211/en/). In addi-
tion, inﬂuenza viruses cause occasional pandemics when an anti-
genically novel virus spills into the human population or when, as
in the case of the 2009 pandemic H1N1 virus, an inﬂuenza virus
that has ceased to circulate among humans for decades reemerges
(Smith et al., 2009). The vastmajority of adults possess pre-existing
immunity to inﬂuenza viruses because of prior infection and/or
vaccination (Sasaki et al., 2007). Thus, inﬂuenza represents a direct
and unique challenge to the human immunological memory.
Immunological memory is typically established following
immunization or infections, and it is the corner-stone for the
success of all prophylactic vaccines (Ahmed and Gray, 1996).
Immunological memory is established in the cellular (CD4 and
CD8 T cells) and humoral (B cells) immune compartments. Two
B cell populations are responsible for sustaining the humoral
immune memory: the long-lived plasma cells (PCs) and memory
B cells (Slifka and Ahmed, 1998; Yoshida et al., 2010). Long-lived
PCs are mainly concentrated in the bone marrow where stromal
and other cell types provide ligands that promote their long-term
survival. Long-lived PCs secrete antigen-speciﬁc antibodies for
protracted periods of time (Slifka and Ahmed, 1998; Manz et al.,
2002; Yoshida et al., 2010). Whether in blood or on mucosal sur-
faces, these antibodies represent the ﬁrst line of pathogen-speciﬁc
defense against re-infection. Unlike long-lived PCs, signiﬁcant
proportions of memory B cells can be isolated from peripheral
blood in humans. Memory B cells rapidly proliferate and dif-
ferentiate into antibody-secreting PCs upon re-encountering the
immunizing antigen or pathogen.
Although protective vaccines against inﬂuenza viruses have
been introduced several decades ago, a thorough understanding
of the role of memory B cells in mediating protection against
inﬂuenza virus challenge remains poorly deﬁned. Here, we will
discuss recent advances, and yet to be answered questions, regard-
ing the role of cross-reactive memory B cell responses elicited
by either infection or vaccination in protection against inﬂuenza.
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Cross-reactive or broad immunity to inﬂuenza viruses has been
described using several terms such as heterotypic, heterosubtypic,
and cross-neutralizing interchangeably. Here, we used the term
cross-reactive in its broadest sense that is to describe B cell tar-
geting of epitopes broadly conserved not only among different
inﬂuenza virus subtypes but also among different viruses within
the same subtype.
ANTIBODY RESPONSES TO INFLUENZA VIRUS HA:
CATCHING A CONSTANTLY MOVING TARGET
Preformed, neutralizing antibodies in serum or, preferably, on the
airway mucosal surface are the best protective measure against
inﬂuenza infection. Viral surface glycoproteins are the prime tar-
gets of protective antibodies. Binding to these glycoproteins can
block initial viral attachment and the subsequent establishment of
infection, thus providing “sterilizing protection” (Gerhard, 2001).
The major two viral surface glycoproteins are the HA and the
neuraminidase (NA). HA is the primary target of infection- and
immunization-induced protective antibodies generated against
inﬂuenza viruses (Wilson and Cox, 1990; Skehel and Wiley, 2000).
HA is a homotrimer that mediates inﬂuenza virus binding to its
sialic acid receptors on lung epithelial cells leading to virus entry
via receptor-mediated endocytosis. In addition, once inside the
endocytic vesicle, HA mediates a pH-dependent virus membrane
fusion with the endosomal membrane, releasing viral genomic
materials into the cytosol (Wilson andCox,1990; Skehel andWiley,
2000).
To date, 16 antigenically distinct HA subtypes have been char-
acterized. These subtypes are phylogenetically classiﬁed into group
1 (H1, H2, H5, H6, H8, H9, H11, H12, H13, and H16) and group
2 (H3, H4, H7, H10, H14, and H15) HA molecules (Figure 1;
Nabel and Fauci, 2010; Sui et al., 2011). Screening viral escape
mutants have revealed that anti-HA antibodies primarily target
few immunodominant epitopes within the globular head region
of the HA molecule. For example, in the inﬂuenza H1 HA ﬁve
immunodominant epitopes (Sa, Sb, Ca1, Ca2, and Cb) were
mapped (Figure 2; Caton et al., 1982; Wilson and Cox, 1990).
Expectedly, these epitopes are located around the receptor-binding
domain within the HA globular head. While antibodies target-
ing such epitopes are potentially neutralizing and protective, they
are strain-speciﬁc, and thus lack the much-desired broad cross-
neutralizing activity to different HA subtypes. Moreover, single
amino acid mutations that accumulate over time within these
immunodominant epitopes allow inﬂuenza viruses to escape exist-
ing immunity. This process is known as the antigenic drift. On the
other hand, human monoclonal antibodies (mAbs) that recognize
the globular head immunodominant epitopes across drift vari-
ants of the same inﬂuenza HA subtype and even across different
HA subtypes have been characterized (Table 1; Corti et al., 2010;
Krause et al., 2011; Whittle et al., 2011; Wrammert et al., 2011).
This indicates that even within these hypervariable globular head
epitopes there are residues that are conserved (possibly due to the
structural and functional requirements for interaction with the
sialic acid receptors), and thus constitute an important target for
broad neutralizing antibodies. It can be speculated that changes
within these conserved residues signiﬁcantly affect virus ﬁtness.
FIGURE 1 | Phylogenetic analysis of the 16 influenza HA subtypes.The
diagram was adapted with permission from Nabel and Fauci (2010).
Apart from the immunodominant HA head epitopes, at least
two epitopes within the HA stalk (or HA2) region have been iden-
tiﬁed as potential targets for an interesting group of murine and
human mAbs (Okuno et al., 1993; Throsby et al., 2008; Ekiert
et al., 2009; Sui et al., 2009; Corti et al., 2010; Wrammert et al.,
2011). The striking advantage of such epitopes is that they are
more conserved across different inﬂuenza HA subtypes compared
to HA head ones. Therefore, antibodies targeting HA stalk region
can be broadly neutralizing. Indeed, some mAbs in this group
(CR6261 and F10) showed a remarkable broad neutralizing activ-
ity against inﬂuenza viruses belonging to all group 1 HAs (Ekiert
et al., 2009; Sui et al., 2009). Ekiert et al. (2011) have recently
demonstrated the existenceof a similarly conserved epitope among
group 2 HAs as well. The latter epitope is the target of CR8020,
a human mAb that can neutralize all group 2 inﬂuenza viruses
(Ekiert et al., 2011). Corti et al. (2011) were able to isolate a
human mAb that is able to neutralize all viruses from group A
and group B HAs. This pan-neutralizing mAb or FI6 was isolated
through extensive screening of mAbs derived from recently gen-
erated antibody-secreting cells (ASCs) that produced antibodies
cross-reacted with H1, H5, and H7 HAs (Corti et al., 2011). It
is currently difﬁcult to precisely determine the frequency of HA
stem-targeting B cells among inﬂuenza-speciﬁc memory B cell
pool, but the fact that out of more than 13,000 mAbs (over 90%
of which is inﬂuenza-speciﬁc) screened from one donor only a
few FI6-like mAbs were detected gives a glimpse of how rare such
speciﬁcity can be in humans (Corti et al., 2011). Structural stud-
ies have revealed that similarly to CR6261 and F10, FI6 bound
to an epitope in the F subdomain within the HA stem region.
However, and in contrast to CR6261 and F10, the binding of
FI6 to HA is mediated by its remarkably long heavy chain com-
plementarity determining region 3 or HCDR3 (out of the three
HCDRs) and that light chain CDR1 (LCDR1) also contributes
to the binding (Corti et al., 2011). The mechanism by which
anti-stem antibodies neutralize inﬂuenza viruses is not entirely
clear, but the observation that CR6261 and FI6 can inhibit virus-
mediated syncytia formation but not hemagglutination suggest
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FIGURE 2 | Comparisons between the features of influenza HA globular
head epitopes and HA stem region epitopes. A structural view of the H1
HA molecule (monomer, A/PR8/34) showing the different globular head
epitopes (red circles) and their localization close to the receptor-binding
domain (brown). The number of (+) signs was arbitrarily determined. Figure
was prepared using Chimera (Pettersen et al., 2004).
that they interfere with the virus membrane fusion step (Corti
et al., 2011).
The ﬁrst evidence of the protective potential of HA stem-
targeting antibodies dates back to 1993 when Okuno et al. (1993,
1994) described C179, a murine mAb that cross-reacted with H1
and H2, but not H3, HA subtypes. C179 protected mice from
a lethal H1 challenge when administered 1 day prior, or 2 days
after, virus challenge (Okuno et al., 1993, 1994). Recently, another
murine mAb, 12D1, was generated following an immunization
schedule designed to boost B cells targeting conserved epitopes on
the H3 HA (Wang et al., 2010a). The same group then later showed
that immunizing mice with the peptide suggested to enclose the
epitope targeted by 12D1 afforded protection for mice against
H3N2, H1N1, and H5N1 inﬂuenza viruses’ challenge (Wang et al.,
2010b). Finally,Wei et al. reported a prime–boost inﬂuenza immu-
nization strategy that enriched the anti-HA-antibody responses
with those targeting the conserved stem epitopes. The immuniza-
tion provided protection against a variety of H1N1 viruses in mice
and ferrets (Wei et al., 2010). The same strategy showed promising
results when used to elicit antibodies against H5 HA in humans
(Ledgerwood et al., 2011).
MEMORY B CELL RESPONSES TO INFLUENZA VIRUS
VACCINATION IN HUMANS
Human inﬂuenza vaccines are designed to elicit antibody
responses to HA and NA and, more importantly, to induce the
generation of persistent antigen-speciﬁc memory B cells. How-
ever, due to inﬂuenza antigenic drift, it is necessary to perform an
annual revision of the antigens included in human seasonal vac-
cines to ensure that they match the circulating inﬂuenza viruses.
Currently, human annual vaccines contain antigens from three dif-
ferent inﬂuenza viruses: H1N1, and H3N2 inﬂuenza A viruses and
an inﬂuenza B virus. The vaccines are provided in two forms; the
inactivated, subunit form and the live attenuated form. Studying
primary B cell responses to inﬂuenza vaccines in humans is difﬁ-
cult due to the wide prevalence of pre-existing immunity. Several
studies have already demonstrated that the vast majority of adults
and even older children possess low but consistent base line levels
of inﬂuenza virus-speciﬁc IgG memory B cells (0.1–0.5% of total
IgG memory B cells; Sasaki et al., 2007). Using the 2005/2006 and
2006/2007 seasonal vaccine formulations, we demonstrated that,
at least in adults, the inﬂuenza-speciﬁc ASCs response to seasonal
vaccines peaks around 1week post-immunization, and is charac-
terized by several features that are reminiscent of memory B cell
responses such as the enhancedkinetics of theASCs generation, the
predominance of isotype switched, highly mutated IgG secreting
cells among responding ASCs (Wrammert et al., 2008). Mea-
suring the frequency, kinetics, and speciﬁcity of antigen-speciﬁc
memory B cells post-vaccination has been technically challeng-
ing. Tracking memory B cells by ﬂow cytometry using ﬂuorescent
antigen has been difﬁcult mainly due to the complexity of the
HA and NA molecules. Using an ex vivo ELISPOT assay in which
memory B cells are polyclonally activated, we have shown that
Inﬂuenza-speciﬁc IgG memory B cells are transiently boosted
after immunization (peaking at 2–4weeks post-immunizations).
Pinna et al. (2009) developed a similar assay in which they selec-
tively activate – using the TLR7/8 agonist R848 and IL-2 – and
clone memory B cells from total peripheral blood monocytes
(PBMCs). Using this method, the authors measured the kinet-
ics of inﬂuenza-speciﬁc memory B cells generation following
immunization and demonstrated that it peaks at day 14 post-
immunization. Several aspects of the memory B cell responses
to inﬂuenza immunization in humans remain largely undeﬁned.
For example, what is the ﬁne speciﬁcity (also cross-reactivity
and neutralizing activity) of the antibodies secreted by reacti-
vated memory B cells? How does inﬂuenza infection affect the
reactivity spectrum of the memory B cell pool? Other important
aspects include the differences in kinetics, magnitude, and quality
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Table 1 | Examples of cross-reactive human monoclonal antibodies that bind to HA globular head epitopes.
Monoclonal
antibody
Neutralization spectrum Target
epitope
B cell source and
mAb isolation method
VH gene
usage
Protection in
animal models
Reference
CH65 H1 HAs (H1 strains
isolated prior to 1977 were
not tested) with the
exception of
A/USSR/90/1977,
A/Texas/36/1991,
A/Wellington/47/1992,
A/Shanghai/8/1996,
A/Neimenggu/52/2002,
and A/California/07/2009
HA globular
head – Sb
epitope
Plasmablasts (day 7
post-vaccination) – cloning
and expression of the IG VH
and VL chains.
VH 1-2 Not available Whittle et al.
(2011)
5J8 H1 HAs with the exception
of A/Brisbane/59/2007 and
A/New Caledonia/20/1999.
Showed HAI activity
against A/South
Carolina/1/1918 and A/New
Jersey/11/1976 but
neutralization titers were
not determined.
HA globular
head –
between
receptor-
binding
domain and
Ca2 epitope
Epstein–Barr virus (EBV)
transformed peripheral blood
mononuclear cells – cloning
and expression of the IG VH
and VL chains.
VH 4-b*01 F Protected mice against
1918 (H1N1) inﬂuenza
virus strain
Krause et al.
(2011)
1009-3B06 H1 HAs (with the
exception of A/PR/8/34)
HA globular
head – Sa/Sb
region
Plasmablasts (induced by
the 2009 pandemic H1N1
infection) – cloning and
expression of the IG VH and
VL chains.
VH 4-39 Protected mice against
A/FM/1/47 (H1N1) and
A/California/04/09 (H1N1)
but not against A/PR/8/34
(H1N1)
Wrammert
et al. (2011)
FE17 H1 HAs (with the
exception of A/New
Jersey/11/1976 and
A/California/07/2009) and
H5 HAs (with the
exception of
A/Indonesia/5/2005 and
A/Anhui/1/2005)
HA globular
head – Ca2
epitope
Epstein–Barr virus (EBV)
transformed peripheral blood
mononuclear cells
VH 4-39*01 Protected mice against
A/PR/8/34 (H1N1) and
A/Vietnam/1204/04
(H5N1) but not against
A/Indonesia/5/05 (H5N1),
A/teal/Hong
Kong/W312/97 (H6N1), or
A/Netherlands/219/03
(H7N7)
Corti et al.
(2010)
of immune responses to inactivated subunit vs. live attenuated
inﬂuenza vaccines in inﬂuenza-naïve individuals.
ROLE OF MEMORY B CELLS IN CROSS-PROTECTION
AGAINST INFLUENZA: THE 2009 H1N1 PANDEMIC EXAMPLE
Apart from the annual epidemics caused by drift variants of
seasonal inﬂuenza viruses, inﬂuenza viruses cause occasional pan-
demics. While inﬂuenza drift variants usually emerge as a result
of few amino acid mutations within the immunodominant head
epitopes, the 2009 pandemic H1 HA had a remarkable 10-fold
increase in HA variability compared to H1 HAs from earlier sea-
sons (Han and Marasco, 2011). The bulk of these changes are
concentrated within the HA globular head (Han and Marasco,
2011). The HA stem region remained relatively conserved between
the pandemic and H1 HA from prior seasonal strains. This
begged the obvious question: if the broadly neutralizing HA stem-
speciﬁc antibodies exist in humans and can be boosted follow-
ing inﬂuenza seasonal immunization, why did the 2009 H1N1
inﬂuenza pandemic show such high infectivity among young
adults with history of previous inﬂuenza exposure? And why, in
general, inﬂuenza is still a serious public health problem?
One possible explanation for this puzzle is that the titers of
HA stem-speciﬁc antibodies are too low to provide protection,
which in turn might be due to the low frequency of HA stem-
speciﬁc B cells participating in the primary response to inﬂuenza
immunization or infection compared to the immunodominant
HA head-speciﬁc ones resulting in a lower frequency of precursor
memoryB cellswith such speciﬁcity.And thus upon re-exposure, it
becomes difﬁcult to boost HA stem-speciﬁc memory B cells to dif-
ferentiate into ASCs, as they are outcompeted by HA head-speciﬁc
memory B cells for the antigen, which in turn result in waning
of the former cells over time. Surprisingly, in individuals infected
with the 2009 pandemicH1N1,out of the 11 neutralizing, anti-HA
mAbs retrieved from peripheral ASCs, 9 mAbs were cross-reactive
targeting the conserved epitopes in the HA stem region (Wram-
mert et al., 2011). We hypothesized that the signiﬁcant changes
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in the immunodominant globular head epitopes of the pandemic
H1 HA compared to the contemporary seasonal H1 HAs lead to
decreased competition for antigen among pre-existing memory B
cells, which in turn allowed for the expansion of the subdominant
stem-speciﬁc memory B cells.
Interestingly, the incidence of infection and mortality from the
2009 inﬂuenza pandemic was lowest among the elderly especially
those aged >65 years (Chowell et al., 2009; Dawood et al., 2009;
Jain et al., 2009). While such protection can be attributed to the
accumulation of memory B cells or serum antibodies that are spe-
ciﬁc to the conserved cross-reactive epitopes, there are no data that
either support or contradict this possibility. Another explanation
for the observed protection would be the close antigenic related-
ness between the HA of the 2009 pandemic H1N1 viruses and that
of H1N1 viruses circulated after the 1918 pandemic and prior to
1950 or that of the swine-origin H1N1 (A/NJ/76; Hancock et al.,
2009; Skowronski et al., 2011). Results from a recent study support
the latter explanation showing that the elderly elicited superior
responses to the 2009 H1N1 monovalent immunization in com-
parison to young adults. These responses were largely directed to
the globular head epitopes (Skowronski et al., 2011). There are still
openquestions that are yet to be answered. For example,what is the
frequency of HA stem-speciﬁc memory B cells? Can such memory
B cells be efﬁciently boosted with the regular inﬂuenza vaccines?
CAN ADJUVANTS HELP?
Adjuvants have been used with human inﬂuenza vaccines for
decades. For split or subunit inﬂuenza vaccines, the use of adju-
vants (especially with antigens derived from avian inﬂuenza
viruses) is recommended to enhance their intrinsic immunogenic-
ity (Treanor et al., 2006). Currently, two main classes of adjuvants
are being used with human inﬂuenza vaccines; the insoluble alu-
minum salts or alum and the oil-in-water emulsion adjuvants
such as MF59 and AS03. These adjuvants were empirically devel-
oped and the mechanisms through which they potentiate immune
responses are not fully understood. Assuming that the frequency
of memory B cells that are speciﬁc to conserved HA epitopes are
relatively low due to the intrinsic poor immunogenicity of the epi-
topes or due to the immunodominance of the HA globular head
epitopes, can adjuvants help in re-engaging these cells in response
to inﬂuenza immunization. Data from immunization studies in
combination with oil-in-water emulsion based adjuvants have
been promising in this respect. For example, MF59-adjuvanted
inﬂuenza vaccines elicited not only a signiﬁcantly higher antibody
titers but also greater cross-reactive antibody responses (Stephen-
son et al., 2005; Banzhoff et al., 2008). Moreover, Golding and
colleagues have shown that MF59 expands the diversity of the
antibody responses to human inﬂuenza vaccines including H5N1
and the 2009 H1N1 pandemic monovalent inﬂuenza vaccines
(Khurana et al., 2010, 2011). The authors examined the binding
patterns of sera obtained from individuals immunizedwithMF59-
adjuvanted vs. unadjuvanted inﬂuenza vaccine to whole inﬂuenza
genome fragment phage display libraries (Khurana et al., 2010,
2011). In contrast to prevaccination andunadjuvanted vaccination
sera that predominantly bound to linear epitopes within the HA2
region, MF59 increased the number of recognized fragments
mapped to the HA1 region and NA protein. These ﬁndings are
important as they shed light on the impact of adjuvants on the
breadth of antibody responses to inﬂuenza vaccines. However,
the question remains whether the “broadening” of the antibody
responses observed with adjuvanted vaccines is a result of activa-
tion of a naïve B cell population that targeted novel epitopeswithin
the immunizing antigen or simply due to more efﬁcient recruit-
ment of a broader repertoire of the inﬂuenza-speciﬁc memory B
cells.
CONCLUDING REMARKS
Recent advances in techniques used in the isolation of human
mAbs together with the high resolution three-dimensional struc-
tures of the HA-antibody complexes have greatly expanded our
understanding of the neutralization potential of anti-inﬂuenza
antibodies. This was exempliﬁed by the characterization of the
human mAbs that target conserved inﬂuenza HA stem epitopes
as well as conserved epitopes within the HA globular head.
More importantly, recent data suggest that antibodies that tar-
get these conserved sites can elicited by immunization in humans
(Ledgerwood et al., 2011). It is important that we next focus on
understanding the factors that determine the immunodominance
hierarchy within the inﬂuenza-speciﬁc memory B cell pool, and
how to enrich the B cell responses to immunization with those
that target conserved and neutralizing epitopes on HA, and thus
provide broader cross-protection.
ACKNOWLEDGMENTS
This work was funded in part by National Institutes of
Health (NIH)/National Institute of Allergy and Infectious
Diseases (NIAID) U19-AI057266 with ARRA supplement
funding U19 AI057266-06S2 (R. Ahmed), by NIH/NIAID
HHSN266200700006C Center of Excellence for Inﬂuenza
Research and Surveillance (R. Ahmed), by the Northeast
Biodefense Center U54-AI057158-Lipkin (R. Ahmed).
REFERENCES
Ahmed, R., and Gray, D. (1996).
Immunological memory and
protective immunity: understand-
ing their relation. Science 272,
54–60.
Banzhoff, A., Pellegrini, M., Del Giu-
dice, G., Fragapane, E., Groth,
N., and Podda, A. (2008). MF59-
adjuvanted vaccines for seasonal
and pandemic inﬂuenza prophy-
laxis. Inﬂuenza Other Respi. Viruses
2, 243–249.
Caton, A. J., Brownlee, G. G., Yewdell,
J. W., and Gerhard, W. (1982). The
antigenic structure of the inﬂuenza
virus A/PR/8/34 hemagglutinin (H1
subtype). Cell 31, 417–427.
Chowell, G., Bertozzi, S. M., Colchero,
M. A., Lopez-Gatell, H., Alpuche-
Aranda, C., Hernandez, M., and
Miller, M. A. (2009). Severe
respiratory disease concurrent
with the circulation of H1N1
inﬂuenza. N. Engl. J. Med. 361,
674–679.
Corti, D., Suguitan, A. L. Jr., Pinna, D.,
Silacci, C., Fernandez-Rodriguez, B.
M., Vanzetta, F., Santos, C., Luke,
C. J., Torres-Velez, F. J., Temper-
ton, N. J., Weiss, R. A., Sallusto, F.,
Subbarao, K., and Lanzavecchia, A.
(2010). Heterosubtypic neutralizing
antibodies are produced by indi-
viduals immunized with a seasonal
inﬂuenza vaccine. J. Clin. Invest. 120,
1663–1673.
Corti, D., Voss, J., Gamblin, S. J.,
Codoni, G., Macagno, A., Jarrossay,
D., Vachieri, S. G., Pinna, D.,
Minola, A., Vanzetta, F., Silacci, C.,
Fernandez-Rodriguez, B. M.,
Agatic, G., Bianchi, S., Giacchetto-
Sasselli, I., Calder, L., Sallusto, F.,
Collins, P., Haire, L. F., Temperton,
N., Langedijk, J. P., Skehel, J. J.,
and Lanzavecchia, A. (2011). A
neutralizing antibody selected
from plasma cells that binds to
group 1 and group 2 inﬂuenza
A hemagglutinins. Science 333,
850–856.
www.frontiersin.org March 2012 | Volume 3 | Article 53 | 5
Ellebedy and Ahmed Memory B cell responses to inﬂuenza viruses
Dawood, F. S., Jain, S., Finelli, L., Shaw,
M. W., Lindstrom, S., Garten, R. J.,
Gubareva,L.V.,Xu,X.,Bridges,C. B.,
and Uyeki, T. M. (2009). Emergence
of a novel swine-origin inﬂuenza A
(H1N1) virus in humans. N. Engl. J.
Med. 360, 2605–2615.
Ellebedy, A. H., and Webby, R. J. (2009).
Inﬂuenza vaccines.Vaccine 27,D65–
D68.
Ekiert, D. C., Bhabha, G., Elsliger,
M. A., Friesen, R. H., Jongenee-
len, M., Throsby, M., Goudsmit, J.,
and Wilson, I. A. (2009). Antibody
recognition of a highly conserved
inﬂuenza virus epitope. Science 324,
246–251.
Ekiert, D. C., Friesen, R. H., Bhabha,
G., Kwaks, T., Jongeneelen, M., Yu,
W., Ophorst, C., Cox, F., Korse, H.
J., Brandenburg, B.,Vogels, R., Brak-
enhoff, J. P., Kompier, R., Koldijk,
M. H., Cornelissen, L. A., Poon, L.
L., Peiris, M., Koudstaal, W., Wil-
son, I. A., and Goudsmit, J. (2011).
A highly conserved neutralizing epi-
tope on group 2 inﬂuenza A viruses.
Science 333, 843–850.
Gerhard, W. (2001). The role of
the antibody response in inﬂuenza
virus infection. Curr. Top. Microbiol.
Immunol. 260, 171–190.
Han, T., and Marasco, W. A. (2011).
Structural basis of inﬂuenza virus
neutralization. Ann. N. Y. Acad. Sci.
1217, 178–190.
Hancock, K., Veguilla, V., Lu, X., Zhong,
W., Butler, E. N., Sun, H., Liu, F.,
Dong, L., DeVos, J. R., Gargiullo,
P. M., Brammer, T. L., Cox, N.
J., Tumpey, T. M., and Katz, J.
M. (2009). Cross-reactive antibody
responses to the 2009 pandemic
H1N1 inﬂuenza virus. N. Engl. J.
Med. 361, 1945–1952.
Jain, S., Kamimoto, L., Bramley, A.
M., Schmitz, A. M., Benoit, S. R.,
Louie, J., Sugerman, D. E., Druck-
enmiller, J. K., Ritger, K. A., Chugh,
R., Jasuja, S., Deutscher, M., Chen,
S., Walker, J. D., Duchin, J. S., Lett,
S., Soliva, S., Wells, E. V., Swerd-
low, D., Uyeki, T. M., Fiore, A. E.,
Olsen, S. J., Fry, A. M., Bridges, C. B.,
and Finelli, L. (2009). Hospitalized
patients with 2009 H1N1 inﬂuenza
in the United States. N. Engl. J. Med.
361, 1935–1944.
Khurana, S., Chearwae, W., Castellino,
F.,Manischewitz, J.,King,L. R.,Hon-
orkiewicz, A., Rock, M. T., Edwards,
K. M., Del Giudice, G., Rappuoli,
R., and Golding, H. (2010). Vac-
cines with MF59 adjuvant expand
the antibody repertoire to target pro-
tective sites of pandemic avianH5N1
inﬂuenza virus. Sci. Transl. Med. 2,
15ra15.
Khurana, S., Verma, N., Yewdell, J. W.,
Hilbert,A. K.,Castellino, F., Lattanzi,
M., Del Giudice, G., Rappuoli, R.,
and Golding, H. (2011). MF59 adju-
vant enhances diversity and afﬁn-
ity of antibody-mediated immune
response to pandemic inﬂuenza vac-
cines. Sci. Transl. Med. 3, 85ra48.
Kilbourne, E. D. (1978). Inﬂuenza
as a problem in immunology. J.
Immunol. 120, 1447–1452.
Krause, J. C., Tsibane, T., Tumpey,
T. M., Huffman, C. J., Basler, C.
F., and Crowe, J. E. Jr. (2011). A
broadly neutralizing human mon-
oclonal antibody that recognizes a
conserved, novel epitope on the
globular head of the inﬂuenza H1N1
virus hemagglutinin. J. Virol. 85,
10905–10908.
Ledgerwood, J. E., Wei, C. J., Hu, Z.,
Gordon, I. J., Enama, M. E., Hendel,
C. S., McTamney, P. M., Pearce, M.
B., Yassine, H. M., Boyington, J. C.,
Bailer,R.,Tumpey,T.M.,Koup,R.A.,
Mascola, J. R., Nabel, G. J., and Gra-
ham, B. S. (2011). DNA priming and
inﬂuenza vaccine immunogenicity:
two phase 1 open label randomised
clinical trials. Lancet. Infect. Dis. 11,
916–924.
Manz,R.A.,Arce,S.,Cassese,G.,Hauser,
A. E., Hiepe, F., and Radbruch,
A. (2002). Humoral immunity and
long-lived plasma cells. Curr. Opin.
Immunol. 14, 517–521.
Nabel, G. J., and Fauci, A. S. (2010).
Induction of unnatural immunity:
prospects for a broadly protective
universal inﬂuenza vaccine. Nat.
Med. 16, 1389–1391.
Okuno, Y., Isegawa, Y., Sasao, F., and
Ueda, S. (1993). A common neu-
tralizing epitope conserved between
the hemagglutinins of inﬂuenza A
virus H1 and H2 strains. J. Virol. 67,
2552–2558.
Okuno, Y., Matsumoto, K., Isegawa,
Y., and Ueda, S. (1994). Protec-
tion against the mouse-adapted
A/FM/1/47 strain of inﬂuenza A
virus in mice by a monoclonal anti-
bodywith cross-neutralizing activity
among H1 and H2 strains. J. Virol.
68, 517–520.
Pettersen, E. F., Goddard, T. D., Huang,
C. C., Couch, G. S., Greenblatt, D.
M., Meng, E. C., and Ferrin, T. E.
(2004). UCSF Chimera–a visualiza-
tion system for exploratory research
and analysis. J. Comput. Chem. 25,
1605–1612.
Pinna, D., Corti, D., Jarrossay, D.,
Sallusto, F., and Lanzavecchia, A.
(2009). Clonal dissection of the
human memory B-cell repertoire
following infection and vaccination.
Eur. J. Immunol. 39, 1260–1270.
Sasaki, S., Jaimes, M. C., Holmes, T. H.,
Dekker, C. L., Mahmood, K., Kem-
ble, G. W., Arvin, A. M., and Green-
berg, H. B. (2007). Comparison of
the inﬂuenza virus-speciﬁc effector
and memory B-cell responses to
immunizationof children and adults
with live attenuated or inactivated
inﬂuenza virus vaccines. J. Virol. 81,
215–228.
Skehel, J. J., and Wiley, D. C. (2000).
Receptor binding and membrane
fusion in virus entry: the inﬂuenza
hemagglutinin. Annu. Rev. Biochem.
69, 531–569.
Skowronski, D. M., Hottes, T. S.,
McElhaney, J. E., Janjua, N. Z.,
Sabaiduc, S., Chan, T., Gentleman,
B., Purych, D., Gardy, J., Patrick,
D. M., Brunham, R. C., De Serres,
G., and Petric, M. (2011). Immuno-
epidemiologic correlates of pan-
demic H1N1 surveillance observa-
tions: higher antibody and lower
cell-mediated immune responses
with advanced age. J. Infect. Dis. 203,
158–167.
Slifka, M. K., and Ahmed, R.
(1998). Long-lived plasma cells:
a mechanism for maintaining
persistent antibody produc-
tion. Curr. Opin. Immunol. 10,
252–258.
Smith, G. J., Bahl, J., Vijaykrishna, D.,
Zhang, J., Poon, L. L., Chen, H.,
Webster, R. G., Peiris, J. S., and
Guan, Y. (2009). Dating the emer-
gence of pandemic inﬂuenza viruses.
Proc. Natl. Acad. Sci. U.S.A. 106,
11709–11712.
Stephenson, I., Bugarini, R., Nicholson,
K. G., Podda, A., Wood, J. M.,
Zambon, M. C., and Katz, J. M.
(2005). Cross-reactivity to highly
pathogenic avian inﬂuenza H5N1
viruses after vaccination with non-
adjuvanted and MF59-adjuvanted
inﬂuenza A/Duck/Singapore/97
(H5N3) vaccine: a potential prim-
ing strategy. J. Infect. Dis. 191,
1210–1215.
Sui, J., Hwang, W. C., Perez, S., Wei, G.,
Aird, D., Chen, L. M., Santelli, E.,
Stec, B., Cadwell, G., Ali, M., Wan,
H., Murakami, A., Yammanuru, A.,
Han, T., Cox, N. J., Bankston, L.
A., Donis, R. O., Liddington, R.
C., and Marasco, W. A. (2009).
Structural and functional bases
for broad-spectrum neutralization
of avian and human inﬂuenza A
viruses. Nat. Struct. Mol. Biol. 16,
265–273.
Sui, J., Sheehan, J., Hwang, W.
C., Bankston, L. A., Burchett, S.
K., Huang, C. Y., Liddington, R.
C., Beigel, J. H., and Marasco,
W. A. (2011). Wide prevalence
of heterosubtypic broadly neu-
tralizing human anti-inﬂuenza A
antibodies. Clin. Infect. Dis. 52,
1003–1009.
Throsby, M., van den Brink, E., Jon-
geneelen, M., Poon, L. L., Alard, P.,
Cornelissen, L., Bakker, A., Cox, F.,
van Deventer, E., Guan, Y., Cinatl,
J., ter Meulen, J., Lasters, I., Carsetti,
R., Peiris, M., de Kruif, J., and
Goudsmit, J. (2008). Heterosubtypic
neutralizing monoclonal antibod-
ies cross-protective against H5N1
and H1N1 recovered from human
IgM+ memory B cells. PLoS ONE
3, e3942. doi:10.1371/journal.pone.
0003942
Treanor, J. J., Campbell, J. D.,
Zangwill, K. M., Rowe, T., and
Wolff, M. (2006). Safety and
immunogenicity of an inactivated
subvirion inﬂuenza A (H5N1)
vaccine. N. Engl. J. Med. 354,
1343–1351.
Wang, T. T., Tan, G. S., Hai, R., Pica,
N., Petersen, E., Moran, T. M.,
and Palese, P. (2010a). Broadly
protective monoclonal antibodies
against H3 inﬂuenza viruses fol-
lowing sequential immunization
with different hemagglutinins.
PLoS Pathog. 6, e1000796.
doi:10.1371/journal.ppat.1000796
Wang, T. T., Tan, G. S., Hai, R., Pica,
N., Ngai, L., Ekiert, D. C., Wil-
son, I. A., Garcia-Sastre, A., Moran,
T. M., and Palese, P. (2010b).
Vaccination with a synthetic pep-
tide from the inﬂuenza virus
hemagglutinin provides protection
against distinct viral subtypes.
Proc. Natl. Acad. Sci. U.S.A. 107,
18979–18984.
Webby, R. J., and Webster, R. G.
(2003). Are we ready for pan-
demic inﬂuenza? Science 302,
1519–1522.
Wei, C. J., Boyington, J. C., McTamney,
P. M., Kong, W. P., Pearce, M. B., Xu,
L., Andersen, H., Rao, S., Tumpey,
T. M., Yang, Z. Y., and Nabel,
G. J. (2010). Induction of broadly
neutralizing H1N1 inﬂuenza anti-
bodies by vaccination. Science 329,
1060–1064.
Whittle, J. R., Zhang, R., Khurana, S.,
King, L. R., Manischewitz, J., Gold-
ing, H., Dormitzer, P. R., Haynes,
B. F., Walter, E. B., Moody, M. A.,
Kepler, T. B., Liao, H. X., and Har-
rison, S. C. (2011). Broadly neu-
tralizing human antibody that rec-
ognizes the receptor-binding pocket
of inﬂuenza virus hemagglutinin.
Proc. Natl. Acad. Sci. U.S.A. 108,
14216–14221.
Wilson, I. A., and Cox, N. J. (1990).
Structural basis of immune
Frontiers in Immunology | B Cell Biology March 2012 | Volume 3 | Article 53 | 6
Ellebedy and Ahmed Memory B cell responses to inﬂuenza viruses
recognition of inﬂuenza virus
hemagglutinin.Annu.Rev. Immunol.
8, 737–771.
Wrammert, J., Koutsonanos, D., Li, G.
M., Edupuganti, S., Sui, J., Morris-
sey, M., McCausland, M., Skount-
zou, I., Hornig, M., Lipkin, W. I.,
Mehta, A., Razavi, B., Del Rio, C.,
Zheng, N. Y., Lee, J. H., Huang,
M., Ali, Z., Kaur, K., Andrews, S.,
Amara, R. R., Wang, Y., Das, S. R.,
O’Donnell,C. D.,Yewdell, J.W., Sub-
barao, K., Marasco, W. A., Mulli-
gan, M. J., Compans, R., Ahmed, R.,
and Wilson, P. C. (2011). Broadly
cross-reactive antibodies dominate
the human B cell response against
2009 pandemic H1N1 inﬂuenza
virus infection. J. Exp. Med. 208,
181–193.
Wrammert, J., Smith, K., Miller, J.,
Langley, W. A., Kokko, K., Larsen,
C., Zheng, N. Y., Mays, I., Gar-
man, L., Helms, C., James, J.,
Air, G. M., Capra, J. D., Ahmed,
R., and Wilson, P. C. (2008).
Rapid cloning of high-afﬁnity
human monoclonal antibodies
against inﬂuenza virus. Nature 453,
667–671.
Yoshida, T., Mei, H., Dorner,
T., Hiepe, F., Radbruch, A.,
Fillatreau, S., and Hoyer, B. F.
(2010). Memory B and memory
plasma cells. Immunol. Rev. 237,
117–139.
Conﬂict of Interest Statement: The
authors declare that the research was
conducted in the absence of any
commercial or ﬁnancial relationships
that could be construed as a potential
conﬂict of interest.
Received: 11 January 2012; accepted: 02
March 2012; published online: 30 March
2012.
Citation: Ellebedy AH and Ahmed
R (2012) Re-engaging cross-reactive
memory B cells: the inﬂuenza
puzzle. Front. Immun. 3:53. doi:
10.3389/ﬁmmu.2012.00053
This article was submitted to Frontiers in
B Cell Biology, a specialty of Frontiers in
Immunology.
Copyright © 2012 Ellebedy and Ahmed.
This is an open-access article distributed
under the terms of the Creative Commons
Attribution Non Commercial License,
which permits non-commercial use, dis-
tribution, and reproduction in other
forums, provided the original authors and
source are credited.
www.frontiersin.org March 2012 | Volume 3 | Article 53 | 7
